GlassScriptPhysician profile
Douglas G Moss
NPI 1114016631
$3,811.13
in general payments reported to CMS, 2019-2025
33 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $204 · 2021: $392 · 2022: $872 · 2023: $652 · 2024: $605 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $336.00 | 2019-2022 | |
| Evofem Biosciences, INC. | $315.56 | 2021-2025 | Phexxi, Solosec, Phexx |
| Abbvie INC. | $271.62 | 2019-2023 | |
| Exact Sciences Corporation | $270.95 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $252.92 | 2019-2024 | Evenity, Prolia |
| Millicent US INC | $227.49 | 2019-2025 | Intrarosa, Femlyv |
| Therapeuticsmd, INC. | $219.95 | 2019-2021 | |
| Astellas Pharma US INC | $191.88 | 2022-2025 | Veozah |
| Shield Therapeutics INC | $160.80 | 2023-2025 | Accrufer |
| Pfizer INC. | $158.88 | 2019-2024 | |
| Hologic Sales and Service, LLC | $146.26 | 2020-2025 | Thinprep 2000 Processor, Aptima |
| Vertical Pharmaceuticals, LLC | $114.04 | 2019 | |
| Scynexis, INC. | $102.10 | 2022 | |
| Mayne Pharma Commercial LLC | $98.82 | 2022-2024 | |
| Exeltis, USA INC. | $94.72 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $93.61 | 2023-2025 | Myfembree, Gemtesa |
| Duchesnay USA Incorporated | $81.89 | 2019 | |
| Agile Therapeutics, INC. | $81.59 | 2021-2022 | |
| Daiichi Sankyo INC. | $81.22 | 2022-2024 | Injectafer |
| Ibsa Pharma INC. | $66.86 | 2023-2024 | Tirosint, Licart, Tirosint |
| Myovant Sciences INC. | $63.11 | 2022 | |
| Renovia INC | $57.06 | 2019 | |
| Merck Sharp & Dohme LLC | $54.89 | 2020-2022 | |
| Organon LLC | $51.67 | 2022-2023 | Nexplanon |
| Glaxosmithkline, LLC. | $50.23 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $30.52 | 2019 | |
| Avion Pharmaceuticals | $29.44 | 2019-2022 | |
| Mission Pharmacal Company | $24.16 | 2019 | |
| Coopersurgical, INC. | $23.33 | 2024 | Paragard T 380a |
| Roche Diagnostics Corporation | $16.00 | 2019 | |
| Medline Industries LP | $15.86 | 2024 | |
| Biogen, INC. | $15.08 | 2025 | Zurzuvae |
| Dysis Medical, INC. | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.